Volume 27, Issue 3 (September 2023)                   Physiol Pharmacol 2023, 27(3): 307-318 | Back to browse issues page

XML Print

Abstract:   (329 Views)

Introduction: It has been approved that selective serotonin reuptake inhibitors (SSRIs) may exhibit anti-proliferative or cytotoxic effects on several types of cancers. The aim of the present study was to evaluate the cytotoxic effects of a newly formulated niosome of Escitalopram oxalate on a colorectal cancer cell line.
Methods: The niosomes were prepared using a thin layer hydration method, resulting in particles with a size range between 150 – 450 nm and spherical morphology. Moreover, its permeability release showed 25% in 4 hours. The cytotoxicity evaluation was performed using a quantitative colorimetric MTT assay.
Results: The cell viability of colon cancer cells after treatment with niosomes and pure escitalopram reduced to 28.3 ± 0.83 % and 24.07 ± 0.56%, respectively. However, the cytotoxicity assay of escitalopram-loaded niosomes suggested that the anti-proliferative effect of the niosomal formulation of escitalopram was dose and incubation time-dependent.
Conclusion: These results confirm the potential of the anti-proliferative activity of escitalopram-loaded niosomes. Further application to an in vivo model is needed to study various pharmacokinetic and pharmacodynamics parameters to establish its complete therapeutic potential.

Full-Text [PDF 2468 kb]   (130 Downloads)    
Types of Manuscript: Experimental research article | Subject: Toxicology

1. Akbari V, Abedi D, Pardakhty A, Sadeghi-Aliabadi H. Release studies on ciprofloxacin loaded non-ionic surfactant vesicles. Avicenna J Med Biotechnol 2015; 7: 69.
2. Alvi IA, Madan J, Kaushik D, Sardana S, Pandey RS, Ali A. Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in-vitro release, and cytotoxicity analysis. Anticancer Drugs 2011; 22: 774-782. [DOI:10.1097/CAD.0b013e328346c7d6]
3. Balakrishnan P, Shanmugam S, Lee W S, Lee WM, Kim JO, Oh DH, et al. Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery. Int J Pharm 2009; 377: 1-8. [DOI:10.1016/j.ijpharm.2009.04.020]
4. Balasubramaniam A, Anil Kumar V, Sadasivan Pillai K. Formulation and in vivo evaluation of niosome-encapsulated daunorubicin hydrochloride. Drug Dev Ind Pharm 2002; 28: 1181-1193. [DOI:10.1081/DDC-120015351]
5. Bayindir ZS, Yuksel N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci 2010; 99: 2049-2060. [DOI:10.1002/jps.21944]
6. Bernsdorff C, Wolf A, Winter R, Gratton E. Effect of hydrostatic pressure on water penetration and rotational dynamics in phospholipid-cholesterol bilayers. Biophys J 1997; 72: 1264-1277. [DOI:10.1016/S0006-3495(97)78773-3]
7. Bharti N, Loona S, Khan M. Proniosomes: A recent advancement in nanotechnology as a drug carrier. Int J Pharm Sci Rev Res 2012; 12: 67-75.
8. Bragagni M, Mennini N, Ghelardini C, Mura P. Development and characterization of niosomal formulations of doxorubicin aimed at brain targeting. J Pharm Pharm Sci 2012; 15: 184-196. [DOI:10.18433/J3230M]
9. Burke WJ, Kratochvil CJ. Stereoisomers in psychiatry: the case of escitalopram. Prim Care Companion J Clin Psychiatry 2002; 4: 20. [DOI:10.4088/PCC.v04n0107]
10. Charnvanich D, Vardhanabhuti N, Kulvanich P. Effect of cholesterol on the properties of spray-dried lysozyme-loaded liposomal powders. Aaps Pharmscitech 2010; 11: 832-842. [DOI:10.1208/s12249-010-9442-8]
11. Chen VCH, Hsieh YH, Chen LJ, Hsu TC, Tzang BS. Escitalopram oxalate induces apoptosis in U-87 MG cells and autophagy in GBM 8401 cells. J Cell Mol Med 2018; 22: 1167-1178. [DOI:10.1111/jcmm.13372]
12. Chubak J, Boudreau DM, Rulyak SJ, Mandelson MT. Colorectal cancer risk in relation to antidepressant medication use. Int J Cancer 2011; 128: 227-232. [DOI:10.1002/ijc.25322]
13. Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2009. [DOI:10.1002/14651858.CD006532.pub2]
14. Dikmen M, Cantürk Z, Öztürk Y. Escitalopram oxalate, a selective serotonin reuptake inhibitor, exhibits cytotoxic and apoptotic effects in glioma C6 cells. Acta Neuropsychiatr 2011; 23: 173-178. [DOI:10.1111/j.1601-5215.2011.00550.x]
15. El-Sayed MM, Hussein AK, Sarhan HA, Mansour HF. Flurbiprofen-loaded niosomes-in-gel system improves the ocular bioavailability of flurbiprofen in the aqueous humor. Drug Dev Ind Pharm 2017; 43: 902-910. [DOI:10.1080/03639045.2016.1272120]
16. Ge X, Wei M, He S, Yuan WEJP. Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharm 2019; 11: 55. [DOI:10.3390/pharmaceutics11020055]
17. Ghafelehbashi R, Akbarzadeh I, Yaraki MT, Lajevardi A, Fatemizadeh M, Saremi LH. Preparation, physicochemical properties, in vitro evaluation and release behavior of cephalexin-loaded niosomes. Int J Pharm 2019; 569: 118580. [DOI:10.1016/j.ijpharm.2019.118580]
18. Gil-Ad I, Zolokov A, Lomnitski L, Taler M, Bar M, Luria D, et al. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice. Int J Oncol 2008; 33: 277-286.
19. Hope M, Bally M, Mayer L, Janoff A, Cullis P. Generation of multilamellar and unilamellar phospholipid vesicles. Chem Phys Lipids 1986; 40: 89-107. [DOI:10.1016/0009-3084(86)90065-4]
20. Ingallina C, Rinaldi F, Bogni A, Ponti J, Passeri D, Reggente M, et al. Niosomal approach to brain delivery: Development, characterization and in vitro toxicological studies. Int J Pharm 2016; 511: 969-982. [DOI:10.1016/j.ijpharm.2016.08.002]
21. Jang WJ, Jung SK, Vo TTL, Jeong CH. Anticancer activity of paroxetine in human colon cancer cells: Involvement of MET and ERBB3. J Cell Mol Med 2019; 23: 1106-1115. [DOI:10.1111/jcmm.14011]
22. Kazi KM, Mandal AS, Biswas N, Guha A, Chatterjee S, Behera M, et al. Niosome: a future of targeted drug delivery systems. J Adv Pharm Technol Res 2010; 1: 374. [DOI:10.4103/0110-5558.76435]
23. Kumud U. Development and Evaluation of Bio Nanogels of Selegiline and Escitalopram for Brain Targeting through Ear. 2016.
24. Lawrence M, Chauhan S, Lawrence S, Barlow D. The formation, characterization and stability of non-ionic surfactant vesicles. STP pharma sci 1996; 6: 49-60.
25. Llorca P, Brousse G, Schwan R. Escitalopram for treatment of major depressive disorder in adults. L’Encephale 2005; 31: 490-501. [DOI:10.1016/S0013-7006(05)82410-8]
26. Lockman P, Mumper R, Khan M, Allen D. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 2002; 28: 1-13. [DOI:10.1081/DDC-120001481]
27. Manosroi A, Bauer K. The entrapment of a human insulin-DEAE dextran complex in different compound liposomes. Drug Dev Ind Pharm 1989; 15: 2531-2546. [DOI:10.3109/03639048909052545]
28. Manosroi A, Wongtrakul P, Manosroi J, Sakai H, Sugawara F, Yuasa M, et al. Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Colloids Surf B Biointerfaces 2003; 30: 129-138. [DOI:10.1016/S0927-7765(03)00080-8]
29. Moazeni E, Gilani K, Sotoudegan F, Pardakhty A, Najafabadi A R, Ghalandari R, et al. Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery. J Microencapsul 2010; 27: 618-627. [DOI:10.3109/02652048.2010.506579]
30. Moghassemi S, Parnian E, Hakamivala A, Darzianiazizi M, Vardanjani M M, Kashanian S, et al. Uptake and transport of insulin across intestinal membrane model using trimethyl chitosan coated insulin niosomes. Mater Sci Eng C 2015; 46: 333-340. [DOI:10.1016/j.msec.2014.10.070]
31. Mokhtar M, Sammour OA, Hammad MA, Megrab NA. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm 2008; 361: 104-111. [DOI:10.1016/j.ijpharm.2008.05.031]
32. Montgomery SA, Loft H, Sánchez C, Reines EH, Papp M. Escitalopram (S-enantiomer of citalopram): Clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 2001; 88: 282-286. [DOI:10.1111/j.1600-0773.2001.880511.x]
33. Pardakhty A, Moazeni E, Varshosaz J, Hajhashemi V, Rouholamini Najafabadi A. Pharmacokinetic study of niosome-loaded insulin in diabetic rats. Daru 2011; 19.
34. Patel R. Anti-proliferative effects of selected antidepressant agents on human metastatic breast cancer cell line, MDA-MB-231. Journal 2013.
35. Rajput R, Kumar S, Nag P, Singh M. Fabrication and characterization of chitosan based polymeric escitalopram nanoparticles. J App Pharm Sci 2016; 6: 171-177. [DOI:10.7324/JAPS.2016.60725]
36. Raslan M. Effect of some formulation variables on the entrapment efficiency and in vitro release of ketoprofen from ketoprofen niosomes. J Life Med 2013; 1: 15-22. [DOI:10.14511/jlm.2013.010201]
37. Rochdy Haj-Ahmad R, Ali Elkordy A, Shu Chaw C. In vitro characterisation of Span™ 65 niosomal formulations containing proteins. Curr Drug Deliv 2015; 12: 628-639. [DOI:10.2174/1567201812666150511095432]
38. Ruckmani K, Sankar V. Formulation and optimization of zidovudine niosomes. Aaps pharmscitech 2010; 11: 1119-1127. [DOI:10.1208/s12249-010-9480-2]
39. Sadeghi S, Ehsani P, Cohan RA, Sardari S, Akbarzadeh I, Bakhshandeh H, et al. Design and Physicochemical Characterization of Lysozyme Loaded Niosomal Formulations as a New Controlled Delivery System. Pharm Chem J 2020: 1-10. [DOI:10.1007/s11094-020-02100-6]
40. Sankhyan A, Pawar P. Recent trends in niosome as vesicular drug delivery system. J Appl Pharm Sci 2012; 2: 20-32.
41. Seras-Cansell M, Ollivon M, Lesieur S. Generation of non-ionic monoalkyl amphiphile-cholesterol vesicles: evidence of membrane impermeability to octyl glucoside. STP pharma sci 1996; 6: 12-20. [DOI:10.1021/la950276y]
42. Shaker DS, Shaker MA, Hanafy MS. Cellular uptake, cytotoxicity and in-vivo evaluation of Tamoxifen citrate loaded niosomes. Int J Pharm 2015; 493: 285-294. [DOI:10.1016/j.ijpharm.2015.07.041]
43. Tavano L, Muzzalupo RJC, Biointerfaces SB. Multi-functional vesicles for cancer therapy: the Ultimate magic bullet. Colloids Surf B Biointerfaces 2016 1; 147:161-171. [DOI:10.1016/j.colsurfb.2016.07.060]
44. Taylor C, Pollack M, LeBeau R, Simon N. Anxiety disorders: panic, social anxiety, and generalizedanxiety. Massachusetts General Hospital ComprehensiveClinical Psychiatry. 1st ed. Philadelphia, PA: Elsevier Mosby 2008. [DOI:10.1016/B978-0-323-04743-2.50034-2]
45. Taymouri S, Varshosaz J. Effect of different types of surfactants on the physical properties and stability of carvedilol nano-niosomes. Adv biomed res 2016; 16;5:48. [DOI:10.4103/2277-9175.178781]
46. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J pharma 1998; 172: 33-70. [DOI:10.1016/S0378-5173(98)00169-0]
47. Waddad AY, Abbad S, Yu F, Munyendo WL, Wang J, Lv H, et al. Formulation, characterization and pharmacokinetics of Morin hydrate niosomes prepared from various non-ionic surfactants. Int J pharma 2013; 456: 446-458. [DOI:10.1016/j.ijpharm.2013.08.040]
48. Weiner AL. Liposomes as carriers for polypeptides. Adv Drug Deliv Rev 1989; 3: 307-341. [DOI:10.1016/0169-409X(89)90026-4]
49. Yang H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharma res 2010; 27: 1759-1771. [DOI:10.1007/s11095-010-0141-7]
50. Yoshioka T, Sternberg B, Florence A T. Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85). Int J pharma 1994; 105: 1-6. [DOI:10.1016/0378-5173(94)90228-3]
51. Yuan I, Horng CT, Chen VCH, Chen CH, Chen LJ, Hsu TC, et al. Escitalopram oxalate inhibits proliferation and migration and induces apoptosis in non-small cell lung cancer cells. Oncol Let 2018; 15: 3376-3382. [DOI:10.3892/ol.2017.7687]

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.